Ayahuasca, Ibogaine, and Psychedelics for Addiction: What the Evidence Says

The Psychedelic Renaissance — With Caveats

Interest in psychedelic-assisted therapy for addiction has exploded in recent years. Research institutions like Johns Hopkins, NYU, and Imperial College London are running clinical trials. Media coverage has been largely positive. And a growing number of people are traveling internationally for psychedelic treatments not available in the US.

Colombia, where several psychedelic substances are legal or decriminalized, has become a destination for these treatments. But enthusiasm must be balanced with honesty about what the evidence does and does not support.

Ibogaine: Opioid Withdrawal Interruption

Ibogaine is derived from the root bark of the West African shrub Tabernanthe iboga. Observational studies and case reports suggest that a single dose can dramatically reduce or eliminate opioid withdrawal symptoms and cravings for days to weeks. This has generated significant interest as a potential opioid detox tool.

What the evidence shows: Multiple observational studies report that 50–80% of participants experienced significant reduction in withdrawal severity and cravings. Some report sustained abstinence at 1–3 month follow-up. However, no randomized controlled trials (RCTs) have been completed. The evidence remains Level 3 (case series and observational data).

The cardiac risk: Ibogaine prolongs the QT interval on ECG — a marker for potentially fatal cardiac arrhythmias. Multiple deaths have been reported in ibogaine treatment settings, primarily in individuals with pre-existing cardiac conditions. This risk is real and requires thorough cardiac screening (ECG, electrolyte panel) before treatment and continuous cardiac monitoring during the experience.

Ayahuasca: Limited Evidence for Addiction

Ayahuasca — a DMT-containing brew with deep ceremonial roots in Amazonian indigenous cultures — has been the subject of limited clinical research for addiction. Observational studies in ritual-use communities suggest lower rates of substance abuse among regular ayahuasca users, but these are correlational, not causal. A few small pilot studies show reduced substance use in participants who underwent guided ayahuasca sessions, but sample sizes are very small and lack control groups. The evidence level for ayahuasca as an addiction treatment is Level 3–4.

Psilocybin: The Strongest Clinical Evidence

Psilocybin (the active compound in "magic mushrooms") has the most rigorous clinical evidence among psychedelics for addiction treatment. Phase II trials at Johns Hopkins have shown promising results for both alcohol use disorder and tobacco cessation, with significant abstinence rates at 6-month and 12-month follow-up. Phase III trials are ongoing. The evidence level is approaching Level 2.

Psilocybin's safety profile is more favorable than ibogaine — no significant cardiac risk at therapeutic doses — though it should still be administered in a supported, clinical setting with psychological preparation and integration support.

Legal Status in Colombia

Colombia has a complex relationship with psychoactive substances. Ayahuasca is legal for ceremonial and therapeutic use. Psilocybin-containing mushrooms exist in a legal gray area. Ibogaine is not specifically regulated. This permissive environment has led to a growing industry of retreats and clinics, which vary enormously in quality, medical oversight, and safety standards.

Our Position

We neither promote nor discourage psychedelic-assisted approaches. We encourage anyone considering these treatments to demand full cardiac screening before ibogaine, require medical personnel present during any psychedelic experience, ask about the clinical team's qualifications, understand that these treatments are not replacements for ongoing recovery work (therapy, support groups, lifestyle changes), and consider them as potential adjuncts to — not substitutes for — evidence-based treatment.